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Background: Primary thyroid lymphoma is an uncommon neoplasm frequently associated with lymphocytic
thyroiditis (LT). Once the pathologic diagnosis of primary thyroid lymphoma is established, imaging plays an
important role in tumor staging and evaluating treatment response. The present case discusses the role of
fluorodeoxyglucose positron emission tomography (18F-FDG PET)/computed tomography (CT) in this clinical
setting along with the potential diagnostic challenges.
Patient Findings: A 44-year-old man with a history of LT and hypothyroidism presented with an enlarging
goiter. Initial imaging evaluation showed markedly enlarged gland with bilateral cervical and mediastinal
adenopathy. Histopathologic evaluation confirmed the diagnosis of primary thyroid lymphoma on a back-
ground of LT. An 18F-FDG PET/CT revealed increased uptake in the gland and lymph nodes. Follow-up 18F-
FDG PET/CT after chemotherapy showed interval decrease in FDG uptake in the thyroid gland associated with
interval decrease in the size and metabolic activity of the cervical and superior mediastinal lymph nodes.
Conclusions: The frequent association of LT with primary thyroid lymphoma and the overlap of their clinical
and pathologic findings pose a significant diagnostic challenge. While other imaging techniques are helpful in
evaluating anatomic local and regional extent of primary thyroid lymphoma, 18F-FDG PET/CT can be of an
added value in evaluating its metabolic activity and detecting regional and distant disease as well as in assessing
response to treatment.
Introduction
Primary thyroid lymphoma is an uncommon neoplasmfrequently associated with lymphocytic thyroiditis (LT)
(1–5). The overlap of their clinical and pathologic findings
pose a significant diagnostic challenge. Once the pathologic
diagnosis of primary thyroid lymphoma is established, im-
aging plays an important role in tumor staging and evaluating
treatment response. We discuss the role of fluorodeox-
yglucose positron emission tomography (18F-FDG PET)/CT
in this clinical setting along with the potential diagnostic
challenges.
Patient
A 44-year-old man with a history of LT and hypothyroid-
ism presented with generalized urticaria, difficulty swallow-
ing, and an enlarging goiter. Laboratory evaluation re-
vealed an elevated C-reactive protein, positive antinuclear
antibodies, a thyroglobulin antibody titer >3000 (normal
< 1:100), a thyroid peroxidase antibody titer >1000U/mL
(normal < 30U/mL), and a thyroid stimulating hormone level
of 3.1mIU/L (normal 0.30–5.50mIU/L). Magnetic resonance
imaging of the neck showed severe, diffuse thyromegaly with
an overall gland size of 6· 12· 11 cm with a mass effect upon
the upper esophagus and numerous prominent lymph nodes
in the superior mediastinum (Fig. 1a). A subsequent contrast-
enhanced computed tomography (CT) examination of the
neck and chest revealed multiple enlarged cervical and ante-
rior mediastinal lymph nodes (Fig. 1b). A core needle biopsy
of the thyroid revealed diffuse lymphocytic infiltration with
scant thyroid follicles and a partial right thyroid lobectomy
demonstrated markedly effaced architecture. The thyroid
glandwas replaced by a lymphoid infiltrate of small cells with
irregular nuclear contours and clumped chromatin (Fig. 2).
Occasional reactive germinal centers were present, consistent
with residual LT. Thyroid epitheliumwas difficult to identify,
but small foci were present and readily identifiedwith thyroid
transcription factor 1 (TTF1) immunostaining.Histopathologic
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review of the bone marrow revealed a subtle, primarily in-
terstitial infiltrate of atypical lymphocytes. Atypical circulat-
ing lymphocytes were present in the blood. Flow cytometry
was performed on the thyroid tissue and bone marrow. The
neoplastic T- lymphocytes expressed CD2, CD3, CD4, CD5,
and CD7 (dim). Molecular studies performed on the thyroid
tissue and bone marrow demonstrated a T-cell receptor
gamma gene rearrangement. The differential diagnosis
based on morphology and immunophenotype included
adult T-cell leukemia/lymphoma (ATLL), Sezary syndrome,
T-cell polymorphocytic leukemia (T-PLL), and a peripheral
T-cell lymphoma. A negative study for human T-cell
lymphotrophic virus 1 (HTLV-1) excluded ATLL. T-PLL
typically presents with a higher white blood cell count and
cytogenetic studies revealed no evidence of characteristic
translocations. There were no skin lesions or erythroderma
to suggest Sezary syndrome. Consequently, the features
were most consistent with a peripheral T-cell lymphoma, in
leukemic phase.
A 18F-FDG PET/CT scan was performed for further eval-
uation and staging. This showed a diffusely enlarged thyroid
with heterogeneous increased FDG accumulation with max-
imum standardized uptake (SUVmax) of 9 compared to aver-
age mediastinal blood pool uptake (SUVavg) of 1.2, with
multiple bilateral FDG-avid cervical lymph nodes in levels II
through V and in the superior mediastinum (Fig. 3). A repeat
FDG PET/CT (Fig. 4) following three cycles of cyclophos-
phamide hydroxydaunorubicin oncovin prednisone (CHOP)
chemotherapy revealed an interval decrease in FDG avidity
involving the massively enlarged thyroid gland with SUVmax
of 6.6 (mediastinal blood pool SUVavg of 1.5), associated in-
terval decrease in size, and metabolic activity of the cervical
and superior mediastinal lymph nodes, suggesting a partial
therapeutic response to chemotherapy.
Discussion
Occurring with a slight female predominance and a peak
age incidence between 50 and 80 years, primary thyroid
lymphoma is rare, representing 2%–5% of all thyroid malig-
nancies and < 2% of extra-nodal lymphoma (1,2). Thyroid
lymphoma is most commonly associated with LT, with an
overall 67–80-fold higher risk of developing thyroid lym-
phoma compared to the general population. Additionally,
0.5% of patients with LT will develop thyroid lymphoma (3–
5). The time interval between diagnosis of LT and the devel-
opment of thyroid lymphoma is *10 years (4). The most
common type of thyroid lymphoma is diffuse large B-cell
lymphoma, which accounts for almost 70% of cases (6);
however, various histopathologic subtypes have been re-
ported in primary thyroid lymphoma, including low-grade
lymphoma of mucosa-associated lymphoid tissue, Hodgkin’s
lymphoma, Burkitt’s lymphoma, and peripheral T-cell lym-
phoma (1,2). Patients present with a rapidly enlarging goiter,
dysphonia, dysphagia, pain, and hoarseness with constitu-
tional symptoms of malaise, fever, and weight loss (1,2).
Initial diagnosis is often suggested, but not confirmed by fine-
needle aspiration, due to difficulty in distinguishing an infil-
trating lymphoma from background LT. Flow cytometry can
sometimes be useful in evaluating lymphoma in fine needle
aspirates; however, larger tissue specimens obtained by core
biopsy and/or surgical resection are usually required for
definitive tissue diagnosis and cellular subclassification (2).
Although ultrasound imaging of the thyroid gland may
play a role in the initial diagnosis of thyroid lymphoma, it
has limited specificity given variable sonographic features
FIG. 1. (a)Axial T2-weighted
image of the neck at the
level of the thyroid gland
demonstrating massive
heterogeneous enlargement of
the gland extending posterior
the larynx. An enlarged lymph
node is noted in the left
posterior cervical chain
(arrows). (b) Coronal contrast
enhanced computed
tomography (CT) image
showing a massively enlarged
thyroid gland displacing the
carotid arteries laterally. Note
the left lower cervical enlarged
lymph node (arrow).
FIG. 2. Section of thyroid showing a marked infiltrate of
monotonous small lymphocytes with irregular nuclear con-
tours (hematoxylin and eosin, 400 · magnification).
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and significant overlap with other benign and malignant
conditions (3,7).
FDG PET plays an important role in the initial staging and
therapeutic response assessment of lymphoma in general due
to its predictive prognostic value of long-term survival. In-
terim visual changes in uptake and differences in the stan-
dardized uptake values between the initial and follow-up
scans after chemotherapy have been shown to predict out-
come (8). Recent reports have described the clinical utility
of FDG PET in the evaluation of primary thyroid lymphoma
(9–11). Basu et al. reported that FDG PET could be sensitive in
evaluating disease activity at initial staging and follow-up in
FIG. 3. Initial staging FDG
PET/CT: (a) maximum
intensity projection image,
(b) axial PET, and
(c) corresponding axial CT
images demonstrating diffuse
heterogeneous metabolic
activity throughout the
enlarged thyroid gland and
bilateral hypermetabolic
cervical and superior
mediastinal lymph nodes
(arrows).
FIG. 4. Follow-up
fluorodeoxyglucose positron
emission tomography (FDG
PET)/CT following three
cycles of chemotherapy:
(a) maximum intensity
projection image, (b) axial
PET, and (c) corresponding
axial CT images demonstrating
an interval decrease in the FDG
uptake in the thyroid gland
and interval decrease in the size
and metabolic activity of the
cervical lymph nodes
(arrowheads).
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six patients with suspected primary thyroid lymphoma, and
suggested that FDG PETmay detect disease recurrence earlier
than CT alone. Lin also reported the value of FDG PET/CT in
assessing responses to therapy in primary thyroid lymphoma
(10). However, focal FDG accumulation is seen in thyroid
adenomas and thyroid cancers of all types and diffuse FDG
uptake in LT mimicking primary thyroid lymphoma limits
the diagnostic specificity of FDG PET (9,12,13). Massive thy-
roid enlargement associated with diffuse and markedly avid
FDG uptake and the presence of cervical lymph nodes aided
in the distinction of primary lymphoma fromLT in the present
case. However, the frequent association of LTwith PL and the
overlap of their clinical and pathologic findings pose a sig-
nificant challenge, requiring both a high clinical suspicion and
an extensive diagnostic approach in a patient with a rapidly
enlarging thyroid and pre-existing LT. While other imaging
techniques are helpful in evaluating anatomic local and re-
gional extent of primary thyroid lymphoma, 18F-FDG PET/
CT can be of an added value in evaluating its metabolic ac-
tivity and detecting regional and distant disease as well as in
assessing response to treatment.
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